To enable clinical trials in frontotemporal dementia, scientists need biomarkers that distinguish its several underlying pathologies. At a recent conference in Miami, speakers showed data on potential fluid biomarkers and PET tracers that could differentiate the two main proteinopathies, tau and TDP-43. They also discussed nascent markers and debuted an AI algorithm that improves the diagnostic capabilities of FDG-PET scans.
The 16th iteration of the Clinical Trials in Alzheimer’s Disease conference, held October 24-27 in Boston, drew some 2,300 participants, of whom 1,500 crowded into a downtown hotel for the in-person experience while 800 followed proceedings remotely. The meeting started with a session on how efforts to diversify research participation in trials are beginning to yield data on biomarker positivity among different groups, and continued with a focus on which patients might benefit most from amyloid reduction.
The average human brain contains nearly a kilogram of fat. That’s right. The seat of your consciousness—that very thing that might be registering surprise right now—comprises about 60 percent lipid. What does it all do and how might it figure into Alzheimer’s and other neurodegenerative disorders? Scientists who gathered for the 2nd Symposium on Lipids in Brain Disease, shared some answers. From fats that drive proteinopathies and inflammation to others that might bring relief, learn about some of the newest concepts in Tom Fagan’s meeting series.